Abstract 189P
Background
Triple-negative breast cancer (TNBC) is a very heterogeneous breast cancer subtype with an aggressive profile, which has a lower clinical outcome compared to other subtypes. TNBC which expressed androgen receptors (AR) is known to have a prognostic value for breast cancer survival, however, from several studies, it is still controversial.
Methods
A retrospective cohort study using stage I-IV TNBC data from January 2014 to February 2018.Variables that assessed included age, body mass index, histology, tumour size, tumour grade, lymph node, clinical-stage, metastatic status, type of chemotherapy, and AR expression status. Androgen receptor was examined with immunohistochemistry method with cut off ≥1% was considered positive. The result was carried out by two pathologists. The objective was to determine the prognostic value of AR for 3 years overall survival (OS) in AR-positive TNBC with p≤0.05 was considered significant.
Results
There were 78 eligible patients who met the data completeness requirements. There were 8 patients with AR-positive (10%) with a range of 5% to 80%. In univariate analysis, AR was not associated with age, body mass index, tumour histology, tumour size, tumour grade, lymph node status, clinical stage, and chemotherapy. The AR-positive and metastatic status were associated with 3 years worse overall survival with p= 0.028 and 0.033 respectively. In multivariate analysis the two variables were not significant (AR with HR 0.387 (95% CI= 1.226-3.18; p=0.508) and metastatic with HR 2.181 (95% CI= 1.053-2.389; p= 0.508)).
Conclusions
AR expression plays a prognostic role in TNBC where AR-positive is associated with worse outcomes. Due to the controversial issues about the role of AR as a prognostic factor, further research is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr Sardjito Hospital Yogyakarta Indonesia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.